Optimer gets FDA approval, investors sell on the news Print E-mail
By BioMedReports.com Staff   
Friday, 27 May 2011 19:29
Optimer gets FDA approval, investors sell on the news

Below is a look at some of the headlines for companies that made news in the healthcare sector on May 27, 2011.
Shares of Optimer Pharmaceuticals (NASDAQ:OPTR) sold off in afternoon trading Friday after it was reported that the FDA has approved the company's Dificid tablets for intestinal infection. The drug is intended to treat Clostridium difficile, a bacterium that can cause diarrhea and lead to colitis and which afflicts more than 700,000 patients yearly in the U.S. The infection typically affects older patients and can sometimes be fatal. Dificid showed in trials that it worked as well as the current treatment, vancomycin, at treating the infection but also proved more effective at preventing it from returning after three weeks of treatment.
Investors pushed shares of Optimer as high as $14.70 in intra-day trading in anticipation of approval, only to sell off sharply once the FDA news hit the wires. Shares closed Friday trading at $12.87, down $1.12 or 8%. More than 5 million shares traded hands.

Advanced BioMedical Technologies Inc. (OTCQB: ABMT) (PINKSHEETS: ABMT), developer and manufacturer of orthopaedic internal fixation devices, is delighted to announce that the Company has received the maximum amount of USD 244,479.25 for one grant under the U.S. Government's Qualifying Therapeutic Discovery Project, a program created as part of the Patient Protection and Affordable Care Act of 2010.

Boston Scientific Corporation (NYSE:BSX) today announced that it is voluntarily recalling all of its iCross™ Coronary Imaging Catheters used in intravascular ultrasound (IVUS) imaging in patients who are candidates for transluminal coronary interventional procedures.  

CNS Response, Inc. (OTCBB: CNSO) announced today that the company's first Canadian patent and fifth U.S. patent applications have been approved.

Compass Biotechnologies, Inc. (Compass) (OTCBB: COBI) is pleased to announce the appointment of Dr. Joseph Sinkule to the position of President and Chief Operating Officer (COO) of the Company.

Crossroads Systems, Inc. (PINKSHEETS: CRDS)
today announced it will exhibit both current and upcoming data protection and storage solutions in booth # 1116 at the 2011 International MUSE Conference being held May 31-June 3 at Gaylord Opryland in Nashville, Tennessee.

GeckoSystems Intl. Corp, (PINKSHEETS: GOSY) | (http://www.geckosystems.com/) a dynamic leader in the emerging mobile robotics industry revolutionizing their development and usage with "Mobile Robot Solutions for Safety, Security and Service™,"  announced today they have initiated binding arbitration (JAMS Ref. no. 1440003083) seeking damages for alleged violation of their Confidentiality Agreement signed and agreed to by Neil T. Wallace of Williamsburg, VA.

Therma-Med, Inc. (PINKSHEETS: THRA) ("the Company") is pleased to announce plans to commence its working program on its Ag/Zn/Pb hosting mineral claims, situated in the Mining Division of Slocan, B.C., Canada.

Vicor Technologies, Inc. (OTCBB: VCRT) today announced that CEO David H. Fater will present at RetailInvestorConferences.com.  

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus